Takeda Pharmaceutical Company Limited American Depositary Receipt (TKDA)
XMUN 
Summary
TKDA Chart
Takeda's Rich Pipeline Optionality Is Worth A 'Buy'
TAK's FY2025 revenue was about $28.4 billion, which was down 1.7% YoY due to Vyvanse's generic pressure. This remains a growth headwind until their first wave launches. Management is pairing a new transformation program with cost-cutting measures that will target over $1.3 billion in annualized gross savings by FY2028. As such, I believe TAK's long-term bull case depends on three near-term launch candidates (i.e., the first wave) with oveporexton, rusfertide, and zasocitinib.
Takeda Pharmaceutical Q4 Earnings Call Highlights
Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program.
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with a restructuring to centralize corporate functions and reduce costs.
Takeda Pharmaceutical Company Limited American Depositary Receipt (TKDA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Takeda Pharmaceutical Company Limited American Depositary Receipt ever had a stock split?
Takeda Pharmaceutical Company Limited American Depositary Receipt Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Julie So-Young Kim CEO | XMUN Exchange | US8740602052 ISIN |
| JP Country | 47,029 Employees | 30 Sep 2025 Last Dividend | - Last Split | 27 Oct 2008 IPO Date |
Overview
Takeda Pharmaceutical Company Limited stands tall as a beacon in the pharmaceutical industry, tracing its origins back to 1781. With its global headquarters in Tokyo, Japan, Takeda is dedicated to the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Its reach spans both Japan and international markets, testifying to its commitment towards enhancing healthcare around the world. Its portfolio encompasses an array of therapeutic areas including gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. Takeda distinguishes itself through strategic collaborations, licensing agreements, and research partnerships with various entities in the healthcare and biotechnology sectors such as BioMarin, Luxna Biotech, GlaxoSmithKline, Neurocrine Biosciences, Inc., Seagen Inc., and many more. These alliances serve to bolster Takeda’s innovative capabilities and expand its impact on patient care globally.
Products and Services
Takeda Pharmaceutical Company Limited provides a broad spectrum of pharmaceutical products and services catered to diverse medical needs. Some of its notable products include:
- Entyvio: A key product in the area of gastroenterology, offering relief and treatment for specific gastrointestinal conditions.
- Gattex/Revestive, Takecab/Vocinti: Targeting rare gastrointestinal disorders, these products exemplify Takeda’s commitment to addressing less common, but challenging health issues.
- Alofisel, Dexilant, Pantoloc/Controloc: These products further underline Takeda’s strength in developing treatments within the gastroenterological field, offering options for various digestive health concerns.
- Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine: Part of Takeda’s plasma-derived therapies, these products are crucial in treating certain blood disorders, showcasing the company’s contribution to hematological care.
- Takhzyro, Livtencity: Takeda offers these innovative solutions in the realm of immunology, aiming to improve the lives of patients dealing with immune system-related diseases.
- Elaprase, Replagal: In the fight against rare diseases, these therapies represent Takeda’s dedication to providing hope and solutions to patients confronted with less common medical conditions.
- Advate, Flexbumin, Vpriv: These products reflect Takeda’s ongoing efforts to address a variety of health challenges, including but not limited to, hematology and genetic disorders.
- Gammagard Liquid/Kiovig, Hyqvia, Cuvitru: Emphasizing the company’s prowess in immunology, these therapies are aimed at supporting patients with compromised immune systems.
- Exkivity, Ninlaro, Velcade: Oncology is another critical area for Takeda, with these products leading the charge against cancer, offering patients hope and improved outcomes.
- Azilva-F, Lotriga: Dedicating efforts towards cardiovascular health, these medicines provide options for managing high blood pressure, a common concern globally.
- Iclusig, Leuplin/Enantone, Adcetris: Targeting specific types of cancer, these products are part of Takeda’s robust oncology portfolio, aimed at offering specialized treatment options.
- vyvanse/elvanse, Trintellix, Alunbrig: Takeda’s presence in the neuroscience domain is highlighted through these therapies, addressing mental health and neurological conditions.
Through these products and more, Takeda Pharmaceutical Company Limited continues to impact various therapeutic areas, showing its versatility and dedication to improving patient health across the globe.
